Association of chromosome 10 losses and negative prognosis in oligoastrocytomas

被引:26
作者
Bissola, L
Eoli, M
Pollo, B
Merciai, BM
Silvani, A
Salsano, E
Maccagnano, C
Bruzzone, MG
Conti, AMF
Solero, CL
Giombini, S
Broggi, G
Boiardi, A
Finocchiaro, G
机构
[1] Ist Nazl Neurol Besta, Unit Neurooncol & Gene Therapy, Dept Expt Neurol & Diagnost, I-20133 Milan, Italy
[2] Ist Nazl Neurol Besta, Dept Clin Neurol, I-20133 Milan, Italy
[3] Univ Milan, Dept Biol & Genet Med Sci, I-20122 Milan, Italy
[4] Ist Nazl Neurol Besta, Dept Neurosurg, I-20133 Milan, Italy
关键词
D O I
10.1002/ana.10405
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Oligoastrocytomas are mixed gliomas harboring different genetic alterations and with heterogeneous clinical evolution. We have looked for correlations between genetic losses and clinical evolution in 34 oligoastrocytomas. Loss of heterozygosity (LOH) with different microsatellite markers was studied on chromosomes 1p, 10q, 17p, and 19q. LOH on 1p was found in 44% of the tumors, on 10q in 24%, on 17p in 18%, and on 19q in 38%. LOH on 1p and 19q was combined in 29% of the patients. LOH on 1p was associated with significantly longer overall survival (p = 0.0092) and LOH on 10q with shorter overall survival (p = 0.0206). The observation that LOH on 10q predicts a short survival in oligoastrocytomas is novel and provides further evidence that genetic analysis may help to predict the clinical evolution of different gliomas, giving a more rationale basis to therapeutic options.
引用
收藏
页码:842 / 845
页数:4
相关论文
共 17 条
[1]  
Albarosa R, 1996, AM J HUM GENET, V58, P1260
[2]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[3]  
FULTS D, 1992, CANCER RES, V52, P674
[4]   Procarbazine, lomustine, and vincristine (PCV) chemotherapy for Grade III and Grade IV oligoastrocytomas [J].
Kim, L ;
Hochberg, FH ;
Thornton, AF ;
Harsh, GR ;
Patel, H ;
Finkelstein, D ;
Louis, DN .
JOURNAL OF NEUROSURGERY, 1996, 85 (04) :602-607
[5]   SHARED ALLELIC LOSSES ON CHROMOSOMES 1P AND 19Q SUGGEST A COMMON ORIGIN OF OLIGODENDROGLIOMA AND OLIGOASTROCYTOMA [J].
KRAUS, JA ;
KOOPMANN, J ;
KASKEL, P ;
MAINTZ, D ;
BRANDNER, S ;
SCHRAMM, J ;
LOUIS, DN ;
WIESTLER, OD ;
VONDEIMLING, A .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1995, 54 (01) :91-95
[6]   RESPONSE CRITERIA FOR PHASE-II STUDIES OF SUPRATENTORIAL MALIGNANT GLIOMA [J].
MACDONALD, DR ;
CASCINO, TL ;
SCHOLD, SC ;
CAIRNCROSS, JG .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) :1277-1280
[7]   Molecular genetic evidence for subtypes of oligoastrocytomas [J].
Maintz, D ;
Fiedler, K ;
Koopmann, J ;
Rollbrocker, B ;
Nechev, S ;
Lenartz, D ;
Stangl, AP ;
Louis, DN ;
Schramm, J ;
Wiestler, OD ;
vonDeimling, A .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1997, 56 (10) :1098-1104
[8]   Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets [J].
Mueller, W ;
Hartmann, C ;
Hoffmann, A ;
Lanksch, W ;
Kiwit, J ;
Tonn, J ;
Veelken, J ;
Schramm, J ;
Weller, M ;
Wiestler, OD ;
Louis, DN ;
von Deimling, A .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (01) :313-319
[9]  
Rasheed B K, 1999, Curr Opin Oncol, V11, P162
[10]  
REIFENBERGER G, 2000, TUMOURS NERVOUS SYST, P55